Literature DB >> 18455242

C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis.

Huibin Qi1, Erdem Tüzün, Windy Allman, Shamsher S Saini, Zurina R Penabad, Silvia Pierangeli, Premkumar Christadoss.   

Abstract

C5 deficient mice are highly resistant to experimental autoimmune myasthenia gravis (EAMG) despite intact immune response to acetylcholine receptor (AChR), validating the pivotal role played by membrane attack complex (MAC, C5b-9) in neuromuscular junction destruction. To distinguish the significance of C5a from that of C5b in EAMG pathogenesis, C5a receptor (C5aR) knockout (KO) and wild-type (WT) mice were immunized with AChR to induce pathogenic anti-AChR antibodies. In contrast with C5 deficient mice, C5aR KO mice were equally susceptible to EAMG as WT mice and exhibited comparable antibody and lymphocyte proliferation response to AChR implicating that C5a is not involved in EAMG development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455242      PMCID: PMC3645869          DOI: 10.1016/j.jneuroim.2008.03.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

1.  The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease.

Authors:  S O'Barr; N R Cooper
Journal:  J Neuroimmunol       Date:  2000-09-22       Impact factor: 3.478

2.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

3.  C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice.

Authors:  Scott E Wenderfer; Baozhen Ke; Travis J Hollmann; Rick A Wetsel; Hui Yao Lan; Michael C Braun
Journal:  J Am Soc Nephrol       Date:  2005-10-05       Impact factor: 10.121

4.  Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis.

Authors:  M Tsujihata; T Yoshimura; A Satoh; I Kinoshita; H Matsuo; M Mori; S Nagataki
Journal:  Neurology       Date:  1989-10       Impact factor: 9.910

5.  C5a and Fcgamma receptors: a mutual admiration society.

Authors:  John P Atkinson
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

6.  Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice.

Authors:  Varsha Kumar; Syed R Ali; Stephanie Konrad; Jörg Zwirner; J Sjef Verbeek; Reinhold E Schmidt; J Engelbert Gessner
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

7.  Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis.

Authors:  E L Morgan; S Sanderson; W Scholz; D J Noonan; W O Weigle; T E Hugli
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

8.  IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1.

Authors:  Huan Yang; Erdem Tüzün; Dhivyaa Alagappan; Xiang Yu; Benjamin G Scott; Alexander Ischenko; Premkumar Christadoss
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

9.  C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies.

Authors:  Zurina Romay-Penabad; Xiaowei X Liu; Guadalupe Montiel-Manzano; Elizabeth Papalardo De Martínez; Silvia S Pierangeli
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

10.  Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.

Authors:  Erdem Tüzün; Shamsher S Saini; Huan Yang; Dhivyaa Alagappan; Stephen Higgs; Premkumar Christadoss
Journal:  J Neuroimmunol       Date:  2006-03-09       Impact factor: 3.478

View more
  2 in total

Review 1.  The emerging role of complement in neuromuscular disorders.

Authors:  John D Lee; Trent M Woodruff
Journal:  Semin Immunopathol       Date:  2021-10-27       Impact factor: 9.623

2.  Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis.

Authors:  Yan Li; Zhidan Tu; Shiguang Qian; John J Fung; Sanford D Markowitz; Linda L Kusner; Henry J Kaminski; Lina Lu; Feng Lin
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.